Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues

Thrombosis Research

Volumn 85, Issue 1, 1997, Pages 67-75

  Lormeau, Jean Claude ^a   Herault, Jean Pascal ^a   Gaich, Colette ^a   Barzu, Teresa ^a   Van Dinther, Theo G ^b   Visser, Arie ^b   Herbert, Jean Marc ^a  

^a SANOFI   (France)

^b NV ORGANON   (Netherlands)

Author keywords

anti factor Xa; antithrombin III; Org 31540; pentasaccharide; SR 90107A

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; PENTASACCHARIDE; SR 80027A; SR 80327A; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME ACTIVITY; PRIORITY JOURNAL;

FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; OLIGOSACCHARIDES;

EID: 0031034272     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(96)00223-X     Document Type: Article

References (19)

1. CHOAY J, PETITOU M, LORMEAU J C, SINAY P, CASU BJ and GATTI G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun., 116, 492-499, 1983
2. BEGUIN S, CHOAY J and HEMKER HC, The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost., 61, 397-401, 1989.
3. LORMEAU JC, HERAULT JP: The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb. Haemost., 74, 1474-1477, 1995.
4. WALENGA JM, FAREED J, PETITOU M, SAMAMA M, LORMEAU JC, CHOAY J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb. Res., 43, 243-248, 1986.
5. WALENGA JM, PETITOU M, LORMEAU JC, SAMAMA M, FAREED J, CHOAY J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res., 46, 187-198, 1987.
6. HOBBELEN PMJ, VAN DINTHER TG, VOGEL GM, VAN BOECKEL CAA, MOELKER HCT, MEULEMAN DG. Pharmacological profile of the chemically synthetized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb. Haemost., 63, 266-270, 1990.
7. AMAR J, CARANOBE C, SIE P, BONEU B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities : an experimental study in two models of thrombosis in the rabbit. Br. J. Haematol., 76, 94-100, 1990.
8. BONEU B, NECCIARI J, CARIOU R, GABAIG A M, KIEFFER G, DICKINSON J, LAMOND G, MOELKER H, MANT T, MAGNANI H, . Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107A/ORG 31540) with high affinity to antithrombin III . Thromb. Haemost., 74, 1468-1473, 1995.
9. VAN BOECKEL CAA, PETITOU M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew. Chem. Int. Ed. Engl., 32, 1671-1690, 1993.
10. st edition, p 457, 1971.
11. ATHA DH, LORMEAU JC, PETITOU M, ROSENBERG RD, CHOAY J. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochem., 26, 6454-6461, 1987.
12. SCULLY MF. Kinetic considerations on the physiologic control of thrombin and factor Xa. Semin. Thromb. Haemost., 18, 218-222, 1992.
13. SCHOEN P, LINDHOUT T, WILLEMS G, HEMKER C. Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. J. Bio. Chem., 264, 10002-10007, 1989.
14. BARROWCLIFFE TW, CURTIS AD, TOMLISON TP, HUBBARD AR, JOHNSON EA, THOMAS DP. Standardization of low molecular weight heparins a collaborative study. Thromb. Haemost., 54, 675-679, 1985.
15. BARROWCLIFFE TW, CURTIS AD, JOHNSON EA, THOMAS DP. An International Standard for low molecular weight heparin. Thromb. Haemost., 60, 1-7, 1988.
16. DAUTZENBERG M D, BARA L, CORNU P, SAMAMA M. Specific anti-Xa activity of LMWH (Kabi 2165, CY 216, PK 10169) against the first International Standard of LMWH: A collaborative study. Thromb. Haemost., 64, 490-491, 1990.
17. MEULEMAN DG, HOBBELEN PMJ, VAN DINTHER TG, VOGEL GM, VAN BOECKEL CAA, MOELKER HCT. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III sequence: Discovery of compounds with a longer duration of action than the natural pentasaccharide. Sem. Thromb. Haemost., 17, 112-117, 1991.
18. BENDETOWICZ AV, BARA L, SAMAMA MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb. Res., 58, 445-454, 1990.
19. ELLIS V, SCULLY MF, KAKKAR VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem. J., 238, 329-333, 1986.